MDM2 and cancer: Navtemadlin is very potent when compared with other p53-MDM2 PPI inhibitors such as RG7112, SAR299155, and Idasanutlin and has a dose-dependent antitumor activity in vitro in over 20 human cancer cell lines expressing WT p53 and several xenograft models (13).